Glaxosmithkline Plc Adr Stock Gross Profit

GSK Stock

USD 33.70 0.35 1.05%

GlaxoSmithKline PLC ADR fundamentals help investors to digest information that contributes to GlaxoSmithKline PLC's financial success or failures. It also enables traders to predict the movement of GlaxoSmithKline Stock. The fundamental analysis module provides a way to measure GlaxoSmithKline PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GlaxoSmithKline PLC stock.

	Last Reported	Projected for Next Year
Gross Profit	21.3 B	14.6 B
Gross Profit Margin	0.70	0.79

Gross Profit Margin is expected to rise to 0.79 this year, although the value of Gross Profit will most likely fall to about 14.6 B.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

GlaxoSmithKline PLC ADR Company Gross Profit Analysis

GlaxoSmithKline PLC's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current GlaxoSmithKline PLC Gross Profit

19.92 B

Most of GlaxoSmithKline PLC's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GlaxoSmithKline PLC ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

GlaxoSmithKline Gross Profit Driver Correlations

Understanding the fundamental principles of building solid financial models for GlaxoSmithKline PLC is extremely important. It helps to project a fair market value of GlaxoSmithKline Stock properly, considering its historical fundamentals such as Gross Profit. Since GlaxoSmithKline PLC's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of GlaxoSmithKline PLC's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of GlaxoSmithKline PLC's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Capital Stock	Short Term Debt	Common Stock	Retained Earnings	Intangible Assets	Long Term Debt	Good Will	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Treasury Stock	Net Tangible Assets	Long Term Investments	Short Long Term Debt	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital	Cash And Equivalents
Total Assets		0.5	0.9	0.33	-0.02	0.97	0.91	0.7	0.71	0.7	0.11	0.94	0.5	0.95	-0.16	0.23	0.35	0.19	-0.26	0.57	-0.59	0.59	0.4	0.49	0.5	0.2
Total Stockholder Equity	0.5		0.43	-0.44	0.2	0.31	0.48	0.33	0.25	0.33	0.88	0.51	0.38	0.68	-0.23	0.1	0.33	0.13	0.06	0.75	-0.27	0.78	0.7	0.42	0.82	-0.44
Net Debt	0.9	0.43		0.38	-0.01	0.89	0.82	0.65	0.9	0.65	0.07	0.82	0.64	0.84	0.02	0.2	0.42	0.11	-0.05	0.47	-0.49	0.65	0.32	0.58	0.5	0.24
Accounts Payable	0.33	-0.44	0.38		-0.33	0.5	0.3	0.43	0.49	0.43	-0.71	0.3	0.22	0.16	0.18	0.04	0.22	-0.07	-0.19	-0.09	-0.22	-0.11	-0.27	0.15	-0.3	0.26
Short Term Investments	-0.02	0.2	-0.01	-0.33		-0.02	0.17	-0.03	0.0	-0.03	0.24	-0.14	-0.18	0.03	-0.34	0.15	-0.01	0.18	0.17	0.33	-0.16	-0.03	0.36	-0.33	0.44	-0.09
Total Liab	0.97	0.31	0.89	0.5	-0.02		0.91	0.74	0.75	0.74	-0.11	0.88	0.47	0.86	-0.15	0.23	0.31	0.2	-0.27	0.48	-0.63	0.46	0.33	0.42	0.4	0.25
Total Current Assets	0.91	0.48	0.82	0.3	0.17	0.91		0.88	0.65	0.88	0.05	0.72	0.6	0.79	-0.04	-0.04	0.14	0.15	-0.2	0.48	-0.54	0.41	0.41	0.31	0.47	0.13
Capital Stock	0.7	0.33	0.65	0.43	-0.03	0.74	0.88		0.55	1.0	-0.13	0.49	0.74	0.55	0.23	-0.33	-0.01	0.03	-0.16	0.25	-0.4	0.18	0.21	0.14	0.21	-0.02
Short Term Debt	0.71	0.25	0.9	0.49	0.0	0.75	0.65	0.55		0.55	-0.04	0.65	0.56	0.66	0.12	0.25	0.58	-0.1	0.14	0.34	-0.31	0.55	0.19	0.54	0.37	0.21
Common Stock	0.7	0.33	0.65	0.43	-0.03	0.74	0.88	1.0	0.55		-0.13	0.49	0.74	0.55	0.23	-0.33	-0.01	0.03	-0.16	0.25	-0.4	0.18	0.21	0.14	0.21	-0.02
Retained Earnings	0.11	0.88	0.07	-0.71	0.24	-0.11	0.05	-0.13	-0.04	-0.13		0.2	0.03	0.36	-0.3	0.18	0.33	0.04	0.2	0.61	0.01	0.66	0.62	0.32	0.71	-0.47
Intangible Assets	0.94	0.51	0.82	0.3	-0.14	0.88	0.72	0.49	0.65	0.49	0.2		0.38	0.96	-0.26	0.4	0.48	0.22	-0.31	0.61	-0.57	0.7	0.35	0.57	0.51	0.14
Long Term Debt	0.5	0.38	0.64	0.22	-0.18	0.47	0.6	0.74	0.56	0.74	0.03	0.38		0.44	0.65	-0.46	-0.03	-0.19	0.1	0.03	-0.06	0.29	-0.08	0.25	0.12	0.13
Good Will	0.95	0.68	0.84	0.16	0.03	0.86	0.79	0.55	0.66	0.55	0.36	0.96	0.44		-0.26	0.36	0.5	0.21	-0.17	0.73	-0.58	0.76	0.52	0.56	0.67	0.03
Property Plant Equipment	-0.16	-0.23	0.02	0.18	-0.34	-0.15	-0.04	0.23	0.12	0.23	-0.3	-0.26	0.65	-0.26		-0.65	-0.26	-0.59	0.35	-0.64	0.54	-0.34	-0.65	-0.17	-0.56	0.39
Current Deferred Revenue	0.23	0.1	0.2	0.04	0.15	0.23	-0.04	-0.33	0.25	-0.33	0.18	0.4	-0.46	0.36	-0.65		0.73	0.16	0.21	0.57	-0.42	0.46	0.45	0.35	0.49	-0.12
Net Receivables	0.35	0.33	0.42	0.22	-0.01	0.31	0.14	-0.01	0.58	-0.01	0.33	0.48	-0.03	0.5	-0.26	0.73		-0.23	0.42	0.6	-0.17	0.59	0.45	0.46	0.48	-0.22
Treasury Stock	0.19	0.13	0.11	-0.07	0.18	0.2	0.15	0.03	-0.1	0.03	0.04	0.22	-0.19	0.21	-0.59	0.16	-0.23		-0.5	0.37	-0.78	0.22	0.34	0.1	0.33	-0.23
Net Tangible Assets	-0.26	0.06	-0.05	-0.19	0.17	-0.27	-0.2	-0.16	0.14	-0.16	0.2	-0.31	0.1	-0.17	0.35	0.21	0.42	-0.5		0.04	0.24	0.01	0.15	-0.04	0.12	-0.13
Long Term Investments	0.57	0.75	0.47	-0.09	0.33	0.48	0.48	0.25	0.34	0.25	0.61	0.61	0.03	0.73	-0.64	0.57	0.6	0.37	0.04		-0.65	0.76	0.88	0.45	0.92	-0.52
Short Long Term Debt	-0.59	-0.27	-0.49	-0.22	-0.16	-0.63	-0.54	-0.4	-0.31	-0.4	0.01	-0.57	-0.06	-0.58	0.54	-0.42	-0.17	-0.78	0.24	-0.65		-0.4	-0.56	-0.25	-0.53	0.24
Long Term Debt Total	0.59	0.78	0.65	-0.11	-0.03	0.46	0.41	0.18	0.55	0.18	0.66	0.7	0.29	0.76	-0.34	0.46	0.59	0.22	0.01	0.76	-0.4		0.6	0.81	0.83	-0.29
Capital Surpluse	0.4	0.7	0.32	-0.27	0.36	0.33	0.41	0.21	0.19	0.21	0.62	0.35	-0.08	0.52	-0.65	0.45	0.45	0.34	0.15	0.88	-0.56	0.6		0.36	0.87	-0.59
Net Invested Capital	0.49	0.42	0.58	0.15	-0.33	0.42	0.31	0.14	0.54	0.14	0.32	0.57	0.25	0.56	-0.17	0.35	0.46	0.1	-0.04	0.45	-0.25	0.81	0.36		0.52	-0.1
Net Working Capital	0.5	0.82	0.5	-0.3	0.44	0.4	0.47	0.21	0.37	0.21	0.71	0.51	0.12	0.67	-0.56	0.49	0.48	0.33	0.12	0.92	-0.53	0.83	0.87	0.52		-0.47
Cash And Equivalents	0.2	-0.44	0.24	0.26	-0.09	0.25	0.13	-0.02	0.21	-0.02	-0.47	0.14	0.13	0.03	0.39	-0.12	-0.22	-0.23	-0.13	-0.52	0.24	-0.29	-0.59	-0.1	-0.47

Click cells to compare fundamentals

GlaxoSmithKline Gross Profit Historical Pattern

Today, most investors in GlaxoSmithKline PLC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various GlaxoSmithKline PLC's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's gross profit growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of GlaxoSmithKline PLC gross profit as a starting point in their analysis.

GlaxoSmithKline PLC Gross Profit

Timeline

Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Competition

Predict GlaxoSmithKline PLC

Gross Profit Over Time

According to the company disclosure, GlaxoSmithKline PLC ADR reported 19.92 B of gross profit. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The gross profit for all United States stocks is 27.25% higher than that of the company.

GlaxoSmithKline Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GlaxoSmithKline PLC's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GlaxoSmithKline PLC could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline PLC by comparing valuation metrics of similar companies.

GlaxoSmithKline PLC is currently under evaluation in gross profit category among its peers.

GlaxoSmithKline PLC Current Valuation Drivers

We derive many important indicators used in calculating different scores of GlaxoSmithKline PLC from analyzing GlaxoSmithKline PLC's financial statements. These drivers represent accounts that assess GlaxoSmithKline PLC's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of GlaxoSmithKline PLC's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	70.1B	53.6B	52.2B	58.5B	119.8B	125.8B
Enterprise Value	95.9B	74.5B	72.1B	75.7B	134.9B	141.6B

GlaxoSmithKline PLC ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, GlaxoSmithKline PLC's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to GlaxoSmithKline PLC's managers, analysts, and investors.

Environmental

Governance

Social

GlaxoSmithKline Fundamentals

	Return On Equity	0.22
	Return On Asset	0.0724
	Profit Margin	0.08 %
	Operating Margin	0.08 %
	Current Valuation	83.64 B
	Shares Outstanding	2.04 B
	Shares Owned By Insiders	0.06 %
	Shares Owned By Institutions	15.38 %
	Number Of Shares Shorted	16.29 M
	Price To Earning	11.80 X
	Price To Book	3.83 X
	Price To Sales	2.17 X
	Revenue	30.33 B
	Gross Profit	19.92 B
	EBITDA	9.08 B
	Net Income	4.93 B
	Cash And Equivalents	3.72 B
	Cash Per Share	0.32 X
	Total Debt	18.02 B
	Debt To Equity	0.98 %
	Current Ratio	1.43 X
	Book Value Per Share	3.43 X
	Cash Flow From Operations	6.77 B
	Short Ratio	3.29 X
	Earnings Per Share	1.54 X
	Price To Earnings To Growth	0.71 X
	Target Price	45.95
	Number Of Employees	70.21 K
	Beta	0.33
	Market Capitalization	68.04 B
	Total Asset	59.01 B
	Retained Earnings	7.74 B
	Working Capital	(2.42 B)
	Current Asset	16.59 B
	Current Liabilities	13.42 B
	Annual Yield	0.05 %
	Five Year Return	5.32 %
	Net Asset	59.01 B
	Last Dividend Paid	0.61

About GlaxoSmithKline PLC Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:

How To Invest In GlaxoSmithKline

Details

Is GlaxoSmithKline Stock a good investment?

Details

What is GlaxoSmithKline PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out GlaxoSmithKline PLC Piotroski F Score and GlaxoSmithKline PLC Altman Z Score analysis.

You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.28)

Dividend Share

0.61

Earnings Share

1.54

Revenue Per Share

15.38

Quarterly Revenue Growth

(0.02)

The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Glaxosmithkline Plc Adr Stock Gross Profit

GlaxoSmithKline PLC ADR Company Gross Profit Analysis

Gross Profit

Revenue

-

Cost of Revenue

Current GlaxoSmithKline PLC Gross Profit

GlaxoSmithKline Gross Profit Driver Correlations

GlaxoSmithKline Gross Profit Historical Pattern

GlaxoSmithKline Gross Profit Peer Comparison

GlaxoSmithKline PLC Current Valuation Drivers

GlaxoSmithKline PLC ESG Sustainability

GlaxoSmithKline Fundamentals

About GlaxoSmithKline PLC Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY